T-47DHomo sapiens (Human)Cancer cell line
Also known as: T-47-D, T47-D, T47D:A, T47D, T-47D-RU, T74D, T470
Quick Overview
Human breast cancer cell line used in cancer research and drug development.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
Database ID | CVCL_0553 |
---|---|
Species | Homo sapiens (Human) |
Tissue Source | Pleural effusion[UBERON:UBERON_0000175] |
Donor Information
Age | 54 |
---|---|
Age Category | Adult |
Sex | Female |
Subtype Features | luminal ER, PR+ |
Disease Information
Disease | Invasive breast carcinoma of no special type |
---|---|
Lineage | Breast |
Subtype | Breast Invasive Ductal Carcinoma |
OncoTree Code | IDC |
DepMap Information
Source Type | ATCC |
---|---|
Source ID | ACH-000147_source |
Known Sequence Variations
Type | Gene/Protein | Description | Zygosity | Note | Source |
---|---|---|---|---|---|
MutationSimple | PIK3CA | p.His1047Arg (c.3140A>G) | Unspecified | - | PubMed=25926053, PubMed=20570890 |
MutationSimple | TP53 | p.Leu194Phe (c.580C>T) | Homozygous | - | from parent cell line T47D:C4 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Therapeutic reactivation of mutant p53 protein by quinazoline derivatives.
Ding A., Baguley B.C.
Invest. New Drugs 30:2035-2045(2012).
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
The cancer SENESCopedia: a delineation of cancer cell senescence.";
Leite de Oliveira R., Wessels L.F.A., Bernards R.
Cell Rep. 36:109441.1-109441.22(2021).
New generation breast cancer cell lines developed from patient-derived xenografts.
Ferreira-Gonzalez A., Harrell J.C., Kabos P., Sartorius C.A.
Breast Cancer Res. 22:68.1-68.12(2020).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Genetic ancestry analysis reveals misclassification of commonly used cancer cell lines.
Mitra R., Nonn L., Kimbro K.S., Kittles R.A.
Cancer Epidemiol. Biomarkers Prev. 28:1003-1009(2019).
Evaluation of NCI-7 cell line panel as a reference material for clinical proteomics.
Shah P., Whiteley G.R., Zhang H.
J. Proteome Res. 17:2205-2215(2018).
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
Lakhani S.R.
Breast Cancer Res. Treat. 167:289-301(2018).
Glycoproteins in claudin-low breast cancer cell lines have a unique expression profile.
Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.
J. Proteome Res. 16:1391-1400(2017).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
Mob. DNA 7:20.1-20.11(2016).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer.
Eldfors S., Bruck O., Aittokallio T., Kallioniemi O.-P.
BMC Cancer 16:378.1-378.17(2016).
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Vandesompele J.
Sci. Data 3:160052-160052(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
OncoImmunology 3:e954893.1-e954893.12(2014).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
PLoS ONE 9:E92047-E92047(2014).
Differences and homologies of chromosomal alterations within and between breast cancer cell lines: a clustering analysis.
Ramirez-Clavijo S.R., Pasini B., Sapino A.
Mol. Cytogenet. 7:8.1-8.14(2014).
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Hirshfield K.M., Oltvai Z.N., Vazquez A.
Cancer Metab. 1:20.1-20.13(2013).
Modeling precision treatment of breast cancer.";
Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.
Genome Biol. 14:R110.1-R110.14(2013).
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.
Breast Cancer Res. Treat. 142:237-255(2013).
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
McCormick F., Gray J.W.
Cancer Cell 24:450-465(2013).
Cell surface-specific N-glycan profiling in breast cancer.";
Shi S.-L., Chen C.-Y., Li Y.
PLoS ONE 8:E72704-E72704(2013).
Global proteome analysis of the NCI-60 cell line panel.";
Wilhelm M., Kuster B.
Cell Rep. 4:609-620(2013).
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
Cancer Res. 73:4372-4382(2013).
A novel approach for characterizing microsatellite instability in cancer cells.
Lu Y.-H., Soong T.D., Elemento O.
PLoS ONE 8:E63056-E63056(2013).
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Martens J.W.M.
Breast Cancer Res. 15:R33.1-R33.17(2013).
Dynamic DNA methylation across diverse human cell lines and tissues.
Crawford G.E., Absher D.M., Wold B.J., Myers R.M.
Genome Res. 23:555-567(2013).
Molecular characterisation of cell line models for triple-negative breast cancers.
Reis-Filho J.S., Tutt A.
BMC Genomics 13:619.1-619.14(2012).
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Science 336:1040-1044(2012).
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Rottapel R., Neel B.G., Moffat J.
Cancer Discov. 2:172-189(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
Yoon C.N., Chang Y.-T.
PLoS ONE 7:E32096-E32096(2012).
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
PLoS ONE 7:E31628-E31628(2012).
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Ambudkar S.V., Gottesman M.M.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
Cell lines from human breast.";
Leibovitz A.
(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York; USA (1994).
Breast cancer stem cells: tumourspheres and implications for therapy.";
Morrison B.J.
Thesis PhD (2010); Griffith University; Brisbane; Australia.
STR profiling of human cell lines: challenges and possible solutions to the growing problem.
Hart R.P., Furtado M.R.
J. Forensic Res. 2 Suppl. 2:5-5(2011).
Establishment and characterization of a cell line of human breast carcinoma origin.
Chaitcik S., Brenner H.J.
Eur. J. Cancer 15:659-670(1979).
Mutations in p53 as potential molecular markers for human breast cancer.
Runnebaum I.B., Nagarajan M., Bowman M., Soto D., Sukumar S.
Proc. Natl. Acad. Sci. U.S.A. 88:10657-10661(1991).
Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines.
Mullen P., Ritchie A., Langdon S.P., Miller W.R.
Int. J. Cancer 67:816-820(1996).
Normal p53 status and function despite the development of drug resistance in human breast cancer cells.
Gudas J.M., Bates S.E.
Cell Growth Differ. 6:1395-1403(1995).
Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.
Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.
Oncogene 16:2865-2878(1998).
Altered gene expression in drug-resistant human breast cancer cells.
Wosikowski K., Schuurhuis D.H., Kops G.J.P.L., Saceda M., Bates S.E.
Clin. Cancer Res. 3:2405-2414(1997).
Systematic variation in gene expression patterns in human cancer cell lines.
Botstein D., Brown P.O.
Nat. Genet. 24:227-235(2000).
Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping.
Isola J.J., Larsson C.
Genes Chromosomes Cancer 28:308-317(2000).
Molecular cytogenetic analysis of breast cancer cell lines.";
Courtay-Cahen C., Roberts I., Theillet C., Caldas C., Edwards P.A.W.
Br. J. Cancer 83:1309-1317(2000).
Aberrations of chromosome 8 in 16 breast cancer cell lines by comparative genomic hybridization, fluorescence in situ hybridization, and spectral karyotyping.
Isola J.J.
Cancer Genet. Cytogenet. 126:1-7(2001).
Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.
Wolf E., Gabius H.-J.
J. Cancer Res. Clin. Oncol. 127:375-386(2001).
Short tandem repeat profiling provides an international reference standard for human cell lines.
Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.
Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
Assembly of microarrays for genome-wide measurement of DNA copy number.
Pinkel D., Albertson D.G.
Nat. Genet. 29:263-264(2001).
Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene.
Birnbaum D., Chaffanet M.
Genes Chromosomes Cancer 35:204-218(2002).
Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.
Santibanez-Koref M.F., Schlag P.M., Scherneck S.
Genes Chromosomes Cancer 37:29-35(2003).
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Edwards P.A.W., Chaffanet M.
Genes Chromosomes Cancer 37:333-345(2003).
HLA class I and II genotype of the NCI-60 cell lines.";
Morse H.C. 3rd, Stroncek D., Marincola F.M.
J. Transl. Med. 3:11.1-11.8(2005).
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Yamori T.
Mol. Cancer Ther. 4:399-412(2005).
Molecular characterization of breast cancer cell lines by a low-density microarray.
Remacle J.
Int. J. Oncol. 27:881-892(2005).
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.
Cancer Res. 66:41-45(2006).
Comprehensive copy number profiles of breast cancer cell model genomes.
Shadeo A., Lam W.L.
Breast Cancer Res. 8:R9.1-R9.14(2006).
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.
Breast Cancer Res. Treat. 99:97-101(2006).
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mol. Cancer Ther. 5:2606-2612(2006).
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
Cancer Cell 10:515-527(2006).
Profiling and authentication of human cell lines using short tandem repeat (STR) loci: report from the National Cell Bank of Iran.
Azari S., Ahmadi N., Jeddi-Tehrani M., Shokri F.
Biologicals 35:195-202(2007).
Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination.
Berglind H., Pawitan Y., Kato S., Ishioka C., Soussi T.
Cancer Biol. Ther. 7:699-708(2008).
The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression.
Petersen O.W., Gray J.W., Bissell M.J.
Mol. Oncol. 1:84-96(2007).
DNA fingerprinting of the NCI-60 cell line panel.";
Chanock S.J., Weinstein J.N.
Mol. Cancer Ther. 8:713-724(2009).
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
Pollack J.R.
PLoS ONE 4:E6146-E6146(2009).
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.
Breast Cancer Res. Treat. 121:53-64(2010).
Systems-level modeling of cancer-fibroblast interaction.";
Finn S.P., Loda M., Mahmood U., Ramaswamy S.
PLoS ONE 4:E6888-E6888(2009).
Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.
Yamamoto S., Oka M., Hirano T., Sasaki K.
BMC Cancer 10:15.1-15.10(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Reassessment of estrogen receptor expression in human breast cancer cell lines.
Ford C.H.J., Al-Bader M., Al-Ayadhi B., Francis I.
Anticancer Res. 31:521-527(2011).